ArticleAmerican health & drug benefits2016

Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia.

Loretta FalaPubMed ↗Full text ↗

No numbers read from the abstract.